Author

Jiang Dian Wang

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5065522570

Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.

2019 · Jonathan R. Strosberg, Nobumasa Mizuno, et al. · Journal of Clinical Oncology · 24

Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.

2016 · Charles S. Fuchs, Atsushi Ohtsu, et al. · Journal of Clinical Oncology · 17

Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

2019 · Zev A. Wainberg, Harry H. Yoon, et al. · Journal of Clinical Oncology · 16

Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.

2016 · Charles S. Fuchs, Atsushi Ohtsu, et al. · Journal of Clinical Oncology · 6

Works count: 4

Citation count: 63

H-index: 4

I10-index: 3